Blog
RSS FeedPosted by Michael Wonder on 28 Jan 2020
Nasal spray medicine for treatment-resistant depression not recommended by NICE
28 January 2020 - More evidence on the clinical and cost effectiveness of esketamine needed. ...
Posted by Michael Wonder on 28 Jan 2020
Alkermes announces U.S. FDA acceptance of ALKS 3831 new drug application for treatment of schizophrenia and bipolar I disorder
28 January 2020 - Alkermes today announced that the U.S. FDA has accepted for review the company's new drug application ...
Posted by Michael Wonder on 28 Jan 2020
FDA continues strong support of innovation in development of gene therapy products
28 January 2020 - This is a pivotal time in the field of gene therapy as the FDA continues its ...
Posted by Michael Wonder on 28 Jan 2020
It’s the insulin, stupid: how drug pricing’s simplest case study became a top issue for 2020 Democrats
28 January 2020 - Presidential candidates can’t stop talking about insulin. ...
Posted by Michael Wonder on 28 Jan 2020
FDA accepts for priority review Dupixent (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis
28 January 2020 - If approved, Dupixent would be the first biologic medicine available in the U.S. for these children. ...
Posted by Michael Wonder on 28 Jan 2020
Big drug purchasers predict price hikes driven by expensive new therapies
27 January 2020 - More than two dozen big buyers of prescription medicines expect that prices will rise by an ...
Posted by Michael Wonder on 28 Jan 2020
Jubilant Radiopharma Receives Approval from Health Canada for Drax Exametazime
27 January 2020 - Jubilant Radiopharma announced today that the company received approval from Health Canada for Drax Exametazine (Kit ...
Posted by Michael Wonder on 28 Jan 2020
Liquidia submits new drug application for LIQ861 (treprostinil) inhalation powder to U.S. FDA for the treatment of pulmonary arterial hypertension
27 January 2020 - Liquidia Technologies today announced the submission of its New Drug Application (NDA) to the U.S. FDA ...
Posted by Michael Wonder on 28 Jan 2020
Expanded access to cutting edge CAR T-cell therapy
28 January 2020 - The Australian Government is expanding access to a cutting edge and potentially curative cancer therapy for patients ...
Posted by Michael Wonder on 28 Jan 2020
CMS expands coverage of next generation sequencing as a diagnostic tool for patients with breast and ovarian cancer
27 January 2020 - Final decision provides new access to Next Generation Sequencing tests for certain Medicare patients with cancer ...
Posted by Michael Wonder on 28 Jan 2020
US FDA approves only triple-combination tablet with Jardiance for adults with type 2 diabetes
27 January 2020 - Trijardy XR (empagliflozin/linagliptin/metformin hydrochloride extended release tablets) is a once-daily therapy combining three well-established treatments in one ...
Posted by Michael Wonder on 28 Jan 2020
Health Canada approves new indication for Stelara (ustekinumab) for the treatment of adults with moderately to severely active ulcerative colitis
27 January 2020 - In the Phase 3 pivotal trial, nearly 44% of patients receiving Stelara subcutaneous injections every 8 ...
Posted by Michael Wonder on 28 Jan 2020
Genentech submits supplemental biologics license application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer
26 January 2020 - Application is being reviewed under FDA's Real-Time Oncology Review pilot program. ...
Posted by Michael Wonder on 28 Jan 2020
EMA celebrates 25 years advancing public and animal health
27 January 2020 - This week marks EMA’s 25th anniversary. ...
Posted by Michael Wonder on 27 Jan 2020
'Cutting edge' $500,000 treatment for aggressive blood cancers
28 January 2020 - Australians battling highly aggressive blood cancers could start a groundbreaking treatment within weeks, after the federal ...